MARKET

HOOK

HOOK

Hookipa Pharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.17
-0.45
-6.80%
After Hours: 6.17 0 0.00% 17:58 09/24 EDT
OPEN
6.57
PREV CLOSE
6.62
HIGH
6.60
LOW
6.10
VOLUME
404.93K
TURNOVER
--
52 WEEK HIGH
20.00
52 WEEK LOW
6.01
MARKET CAP
184.44M
P/E (TTM)
-2.9371
1D
5D
1M
3M
1Y
5Y
HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers
HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.
Zacks · 09/16 15:24
Hookipa Pharma, Merck Team Up For Phase 2 Head & Neck Cancer Trial
Benzinga · 09/15 12:43
HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced head and neck cancers
Clinical collaboration to assess HB-200 in combination with KEYTRUDA® (pembrolizumab) as first-line treatmentHOOKIPA poised to advance clinical development program with randomized Phase 2 study in 2022 NEW YORK and VIENNA, Austria, Sept. 15, 2021 (GLOBE NE...
GlobeNewswire · 09/15 11:00
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 09/14 11:50
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
NEW YORK and VIENNA, Austria, Sept. 07, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management t...
GlobeNewswire · 09/07 14:00
Shareholders in HOOKIPA Pharma (NASDAQ:HOOK) are in the red if they invested a year ago
It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...
Simply Wall St. · 08/27 13:00
Morgan Stanley Maintains Overweight on HOOKIPA Pharma, Lowers Price Target to $18
Morgan Stanley analyst Vikram Purohit maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Overweight and lowers the price target from $19 to $18.
Benzinga · 08/18 11:41
Morgan Stanley Adjusts Price Target on HOOKIPA Pharma to $18 From $19, Maintains Overweight Rating
MT Newswires · 08/18 09:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HOOK. Analyze the recent business situations of Hookipa Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HOOK stock price target is 22.88 with a high estimate of 28.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 78
Institutional Holdings: 13.91M
% Owned: 46.52%
Shares Outstanding: 29.89M
TypeInstitutionsShares
Increased
25
1.59M
New
19
1.08M
Decreased
13
1.64M
Sold Out
11
131.76K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Jan van de Winkel
Chief Executive Officer/Director
Joern Aldag
Chief Financial Officer/Director
Reinhard Kandera
Executive Vice President
Klaus Orlinger
Chief Technology Officer
Roman Necina
Other
Christine Baker
Other
Igor Matushansky
Independent Director
David Kaufman
Independent Director
Michael Kelly
Independent Director
Christoph Lengauer
Independent Director
Julie O Neill
Independent Director
Jean-Charles Soria
No Data
About HOOK
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company develops immunotherapeutics based on its arenavirus platform that are designed to target and amplify a T cell and immune response to disease. The Company's infectious and oncology product candidates HB-101, HB-201, HB-202 and HB-300. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers. The Company is developing its self-antigen project in this area, HB-300, as a replicating technology-based product candidate in metastatic, hormone-resistant prostate cancer.

Webull offers kinds of Hookipa Pharma Inc stock information, including NASDAQ:HOOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HOOK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HOOK stock methods without spending real money on the virtual paper trading platform.